NASDAQ · Biotechnology

KTTA (KTTA) Stock

$0.45 -2.17% NASDAQ: KTTA Healthcare

Valuation

MetricValue
Price$0.45
Market Cap$3.35M
P/E Ratio-0.25
P/B Ratio0.10
P/S Ratio0.00
EPS (TTM)$-2.91
52-Week High$2.06
52-Week Low$0.28
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-36.36%
ROA-33.33%
ROCE-38.18%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-13.0M$-16.0M$-14.0M$-21.0M
Net Profit$-2.0M$-14.0M$-16.0M$-14.0M$-20.0M
EPS$-1.89$-10.34$-13.01$-12.69$-2.91
Op Margin-29925.7%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$53.0M$45.0M$26.0M$16.0M$60.0M
Total Liabilities$2.0M$3.0M$3.0M$1.0M$5.0M
Cash$53.0M$33.0M$16.0M$7.0M$55.0M
Borrowings$0$1.0M$0$0$0

Latest News

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit GlobeNewswire · Jul 8, 2026 Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity MT Newswires · Jun 30, 2026 Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion GlobeNewswire · Jun 30, 2026 Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment MT Newswires · Jun 16, 2026 Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial GlobeNewswire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-14.0M$-13.0M$-14.0M$-15.2B
Investing Cash Flow$0$-3.0M$0$0$11.0M
Financing Cash Flow$6.0M$-3.0M$-4.0M$0$63.5B
Net Cash Flow$53.0M$-20.0M$-17.0M$-9.0M$48.3B
Free Cash Flow$-3.0M$-14.0M$-13.0M$-14.0M$-15.2B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-319.35%
Quick Ratio35.40
Interest Coverage—
Return 1Y-30.22%
Return 3Y-94.87%
Return 5Y—

Ownership

Insiders Held1.11%
Institutions Held70.34%
Institutions Float Held71.13%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.2,100,0002026-03-31
Squadron Capital Management LLC2,100,0002026-03-31
Vivo Capital, LLC2,100,0002026-03-31
Janus Henderson Group PLC2,100,0002026-03-31
Ameriprise Financial, Inc.1,350,8962026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AIM $0.24 -5.84% -0.09 $801193 0.00%
CYCN $3.57 +0.28% -2.99 $16.71M 0.00%
IBO $0.43 -2.27% -1.61 $5.38M 0.00%
KALA $0.76 +3.59% -0.76 $14.62M 0.00%
NBYNovaBay Pharmaceuticals, Inc. $1.47 -24.62% 0.09 $39.14M 2.72%

About KTTA

KTTA is led by CEO Tiago Reis Marques, employs 4 people, headquartered in US, publicly traded since 2021.

KTTA stock trades at $0.45 with a market capitalization of $3.35M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of 0.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.28 and $2.06, and currently trades 78.2% below its 52-week high.

On profitability, KTTA generates a return on equity (ROE) of -36.36%, return on capital employed of -38.18%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides